Besides, YAP1 is overexpressed in NSCLC and the loss of YAP1 has potential as a clinical marker for predicting NE features (Ito et al., 2016), and YAP1, combined with ASCL1, NEUROD1, and POU2F3, can be used to define SCLC subtypes (Baine et al., 2020). This evidence concerns the gene YAP1 and small cell lung carcinoma.